Nexalin Technology (NASDAQ:NXL) Stock Rating Upgraded by Zacks Research

Nexalin Technology (NASDAQ:NXL) was upgraded by Zacks Research to a “hold” rating in a note issued to investors on Thursday, Zacks reports.

Separately, Weiss Ratings lowered shares of Nexalin Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 25th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Reduce”.

Nexalin Technology Price Performance

Shares of NASDAQ NXL opened at $5.73 on Thursday. The stock’s 50-day moving average is $7.63 and its two-hundred day moving average is $10.69. Nexalin Technology has a 1-year low of $4.00 and a 1-year high of $60.00. The company has a market cap of $4.18 million, a price-to-earnings ratio of -0.40 and a beta of 4.08.

Nexalin Technology (NASDAQ:NXL) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.00) by $2.89. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.09 million. Nexalin Technology had a negative return on equity of 278.24% and a negative net margin of 4,141.94%. Equities research analysts anticipate that Nexalin Technology will post -11.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nexalin Technology

A hedge fund recently bought a new stake in Nexalin Technology stock. PEAK6 LLC acquired a new position in shares of Nexalin Technology, Inc. (NASDAQ:NXL) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 240,210 shares of the company’s stock, valued at approximately $79,000. PEAK6 LLC owned about 1.09% of Nexalin Technology at the end of the most recent quarter. Institutional investors own 0.65% of the company’s stock.

Nexalin Technology News Summary

Here are the key news stories impacting Nexalin Technology this week:

• Positive Sentiment: Nexalin signed an exclusive distribution and local manufacturing agreement for its ANVISA-approved Nexalin Sync™ neurostimulation device in Brazil and six other South American countries. The initial commercialization program covers 100 devices and a potential market of more than 300 million people, offering a possible path toward commercial revenue and larger government or private-sector contracts. Nexalin South America distribution and manufacturing agreement
• Positive Sentiment: Nexalin said it regained compliance with Nasdaq requirements on September 30. This removes an immediate listing threat, although the company remains exposed to further compliance and trading risks. Nexalin regains Nasdaq compliance
• Neutral Sentiment: Trading in NXL was repeatedly paused under Nasdaq’s Limit Up-Limit Down mechanism on October 1, indicating unusually sharp price movements and heightened speculative activity. The halts do not represent a change in the company’s fundamentals.
• Negative Sentiment: Maxim Group expects Nexalin to report a loss of $2.70 per share in both the third and fourth quarters of 2026, a full-year loss of $11.40 per share, and a $9.30 per-share loss in 2027. These forecasts reinforce concerns about near-term profitability, particularly given the company’s very small revenue base and historically negative margins. Maxim Group NXL earnings forecast

Nexalin Technology Company Profile

Nexalin Technology, Inc is a medical technology company focused on developing noninvasive neurostimulation devices designed to support brain health. Its technology uses cranial electrotherapy stimulation to deliver low-level electrical signals through electrodes placed on the head, with the aim of influencing brain activity without surgery or implanted hardware.

The company’s product portfolio includes the Nexalin Gen-2 and Gen-3 devices, which are designed for use in clinical and other supervised settings.